Valuation: Insmed Incorporated

Market Cap 26.21B 22.85B 21.58B 19.59B 36.71B 2,515B 36.86B 258B 99.74B 1,278B 98.44B 96.26B 4,114B P/E 2026 *
-73.3x
P/E 2027 * 162x
Enterprise Value 25.57B 22.3B 21.06B 19.12B 35.83B 2,454B 35.97B 252B 97.33B 1,248B 96.07B 93.94B 4,014B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 8.73x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-3.21%
1 week-7.27%
Current month-1.49%
1 month-6.59%
3 months+25.26%
6 months-15.91%
Current year-31.05%
1 week 118.34
Extreme 118.34
130.78
1 month 117.15
Extreme 117.15
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Director

-25,000 0.0114%
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-3.21%-7.27%-17.73%+351.98% 26.21B
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
+0.04%-0.77%-9.49%+456.14% 14.06B
Average -0.53%+1.41%+32.54%+233.65% 28.89B
Weighted average by Cap. -0.45%+1.33%+34.27%+162.97%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.49B 1.35B 2.53B 173B 2.54B 17.82B 6.88B 88.13B 6.79B 6.64B 284B 2.87B 2.5B 2.36B 2.15B 4.02B 275B 4.04B 28.31B 10.92B 140B 10.78B 10.54B 451B
Net income -350M -306M -289M -262M -491M -33.63B -493M -3.46B -1.33B -17.1B -1.32B -1.29B -55.01B 187M 163M 154M 139M 261M 17.9B 262M 1.84B 710M 9.1B 701M 685M 29.28B
Net Debt -632M -551M -520M -472M -885M -60.63B -889M -6.23B -2.4B -30.82B -2.37B -2.32B -99.18B -1.16B -1.01B -952M -865M -1.62B -111B -1.63B -11.41B -4.4B -56.43B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-09-18 US$120.00 -3.21% 3,445,007
26-09-17 US$123.98 +1.14% 1,592,254
26-09-16 US$122.58 +2.22% 1,434,017
26-09-15 US$119.92 -4.29% 3,364,508
26-09-14 US$125.30 -3.18% 1,610,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
120.00USD
Average target price
199.55USD
Spread / Average Target
+66.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!